Fetale molekulargenetische Blutgruppenbestimmung aus mütterlichem Plasma

T. J. Legler

doi:10.1055/s-0034-1368224

Transfusionsmedizin, Inhaltsverzeichnis

Transfusionsmedizin 2014; 4(2): 73-78
DOI: 10.1055/s-0034-1368224

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Fetale molekulargenetische Blutgruppenbestimmung aus mütterlichem Plasma

Fetal Molecular Blood Group Determination From Maternal Plasma

T. J. Legler

Abteilung Transfusionsmedizin, Universitätsmedizin Göttingen, Göttingen

› Institutsangaben

Abstract

Zusammenfassung

Die fetale molekulargenetische Blutgruppenbestimmung aus mütterlichem Plasma ermöglicht bei einer Patientin mit irregulären Antikörpern in der Schwangerschaft eine Risikoabschätzung und eine individualisierte Überwachung. Nach Analyse zellfreier fetaler DNA im mütterlichen Plasma und Nachweis von Nukleinsäurepolymorphismen, die mit dem betreffenden Blutgruppenantigen assoziiert sind, kann von einer besonderen Gefährdung des Fetus ausgegangen werden. Weist der Test dahingegen darauf hin, dass dem Feten das entsprechende erythrozytäre Antigen fehlt, können die Überwachungsintervalle deutlich verlängert werden. Eine Kontrollreaktion, mit der spezifisch fetale DNA nachgewiesen wird, führt zu einer hohen Genauigkeit des Testverfahrens. Die fetale molekulargenetische Blutgruppenbestimmung könnte zukünftig auch in Deutschland dazu dienen, die präpartale Anti-D-Prophylaxe bei nicht immunisierten Rh-negativen Frauen auf die Fälle zu beschränken, bei denen ein Rh-positives Neugeborenes erwartet wird.

Abstract

Molecular determination of the fetal blood group from maternal plasma in women with irregular red cell antibodies allows a risk assessment and a targeted monitoring regimen. Cell-free fetal DNA in maternal plasma is analyzed and if certain nucleic acid polymorphisms are detected which are associated with the respective blood group antigen, the fetus is at risk to develop a hemolytic disease. If in contrast the test indicates that the respective blood group antigen has not been inherited from the father and is absent on fetal red cells, monitoring can be performed in larger intervals or even stopped. A control reaction is available which indicates that cell-free fetal DNA has been present after nucleic acid extraction. This information is especially important when the blood group allele specific reaction gives a negative result. Thus molecular determination of the fetal blood group from maternal plasma is highly accurate. In future this technology might be applied also in Germany to restrict routine antenatal anti-D prophylaxis to only those Rh-negative women who carry a D-positive fetus.

Schlüsselwörter

Morbus haemolyticus neonatorum - Alloimmunisierung - nicht invasiv - Anti-D-Prophylaxe

Key words

hemolytic disease of the newborn - alloimmunization - non-invasive - anti-D prophylaxis

Volltext

Referenzen

Literatur
1 Daniels G. Blood Group Antibodies in haemolytic Disease of the Fetus and Newborn. In: Hadley A, Soothill P, eds. Alloimmune Disorders of Pregnancy. Cambridge: Cambridge University Press; 2002: 21-40
2 Statistisches Bundesamt. Tiefgegliederte Diagnosedaten der Krankenhauspatientinnen und -patienten 2012. Im Internet: https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/TiefgegliederteDiagnosedaten.html Stand: 03.03.2014
3 Bettelheim D, Panzer S, Reesink HW et al. Monitoring and treatment of anti-D in pregnancy. Vox Sang 2010; 99: 177-192
4 Daniels G, Finning K, Martin P et al. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009; 29: 101-107
5 Tabor A, Bang J, Norgaard-Pedersen B. Feto-maternal haemorrhage associated with genetic amniocentesis: results of a randomized trial. Br J Obstet Gynaecol 1987; 94: 528-534
6 Lo YM, Hjelm NM, Fidler C et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-1738
7 Faas BH, Beuling EA, Christiaens GC et al. Detection of fetal RhD-specific sequences in maternal plasma. Lancet 1998; 352: 1196
8 Lo YM. Fetal DNA in maternal plasma, progress through epigenetics. Ann N Y Acad Sci 2006; 1075: 7
9 Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation?. Placenta 2005; 26: 515-526
10 Chan KC, Zhang J, Hui AB et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004; 50: 88-92
11 Lo YM, Zhang J, Leung TN et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218-224
12 Wagner FF, Flegel WA. RHD gene deletion occurred in the Rhesus box . Blood 2000; 95: 3662-3668
13 Faas BH, Beckers EA, Wildoer P et al. Molecular background of VS and weak C expression in blacks. Transfusion 1997; 37: 38-44
14 Daniels GL, Faas BH, Green CA et al. The VS and V blood group polymorphisms in Africans: a serological and molecular analysis. Transfusion 1998; 38: 951-958
15 Grootkerk-Tax MG, Soussan AA, de Haas M et al. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006; 46: 2142-2148
16 Finning K, Martin P, Summers J et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336: 816-818
17 Müller SP, Bartels I, Stein W et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48: 2292-2301
18 Rijnders RJ, van der Luijt RB, Peters ED et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003; 23: 1042-1044
19 Wikman AT, Tiblad E, Karlsson A et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120: 227-234
20 Zhong XY, Bürk MR, Troeger C et al. Fluctuation of maternal and fetal free extracellular circulatory DNA in maternal plasma. Obstet Gynecol 2000; 96: 991-996
21 Lo YM, Tein MS, Lau TK et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768-775
22 Fernando MR, Chen K, Norton S et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 2010; 30: 418-424
23 Müller SP, Bartels I, Stein W et al. Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn 2011; 31: 1300-1304
24 Barrett AN, Zimmermann BG, Wang D et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One 2011; 6: e25202
25 Daniels G, van der Schoot CE, Olsson ML. Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang 2011; 101: 327-332
26 Chitty LS, van der Schoot CE, Hahn S et al. SAFE–the Special Non-invasive Advances in Fetal and Neonatal Evaluation Network: aims and achievements. Prenat Diagn 2008; 28: 83-88
27 Avent ND. RHD genotyping from maternal plasma: guidelines and technical challenges. Methods Mol Biol 2008; 444: 185-201
28 Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes in D negative Europeans. BMC Genet 2001; 2: 10
29 Dziegiel MH. Noninvasive prenatal screening for RHD: the 1st national antenatal directed anti-D prophylaxis program – the Danish model or a guide to robust prediction of need of anti-D. ISBT Sci Ser 2012; 7: 160-163
30 de Haas M, van der Ploeg CPB, Scheffer PG et al. A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D. ISBT Sci Ser 2012; 7: 164-167
31 de Haas M, van der Schoot E. Prenatal screening. ISBT Sci Ser 2013; 8: 6-10
32 de Haas M, Finning K, Massey E et al. Anti-D prophylaxis: past, present and future. Transfusion Medicine 2014; 24: 1-7
33 Clausen FB. Im Internet:. http://www.cfdna2013.eu/documents/presentations/The%2520Danish%2520Experience%2520cfDNA2013%2520website%2520version.pdf Stand: 05.03.2014
34 Minon JM, Gerard C, Senterre JM et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008; 48: 373-381
35 Metcalfe P, Rigsby P, Tait E et al. An international reference reagent for the detection of RHD and SRY DNA in plasma. Vox Sang 2012; 102: 243-249
36 Chan KC, Ding C, Gerovassili A et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006; 52: 2211-2218
37 Hyland CA, Gardener GJ, Davies H et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust 2009; 191: 21-25
38 Zejskova L, Jancuskova T, Kotlabova K et al. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma–next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol 2010; 89: 241-247
39 Page-Christiaens GC, Bossers B, van der Schoot CE et al. Use of bi-allelic insertion/deletion polymorphisms as a positive control for fetal genotyping in maternal blood: first clinical experience. Ann N Y Acad Sci 2006; 1075: 123-129
40 Bombard AT, Akolekar R, Farkas DH et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011; 31: 802-808
41 Doescher A, Petershofen EK, Wagner FF et al. Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. Transfusion 2013; 53: 353-362
42 Kretschmer V, Legler T. Blutgruppenantigene und -antikörper. In: Thomas L, Hrsg. Labor und Diagnose. 8. Aufl. Band 2. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH; 2012: 1539-1609
43 Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut. Richtlinien zur Gewinnung von Blut und Blutsbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Köln: Deutscher Ärzte-Verlag GmbH; 2010
44 Gemeinsamer Bundesausschuss der Ärzte und Krankenkassen. Richtlinien über die ärztliche Betreuung während der Schwangerschaft und nach der Entbindung („Mutterschafts-Richtlinien“) in der Fassung vom 10. Dezember 1985. Zuletzt geändert am 20. Dezember 2012, veröffentlicht im Bundesanzeiger AT 07. 03. 2013 B7, in Kraft getreten am 8. März 2013.
45 Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-1666
46 Koelewijn JM, Vrijkotte TG, van der Schoot CE et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48: 941-952
47 Legler TJ, Lynen R, Maas JH et al. Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apher Sci 2002; 27: 217-223
48 Gutensohn K, Müller SP, Thomann K et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c, and E status in early pregnancy. BJOG 2010; 117: 722-729
49 Scheffer PG, van der Schoot CE, Page-Christiaens GC et al. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118: 1340-1348
50 Benachi A, Delahaye S, Leticee N et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012; 162: 28-32
51 Macher HC, Noguerol P, Medrano-Campillo P et al. Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta 2012; 413: 490-494
52 Lo YMD, Wainscoat JS. Non-invasive prenatal diagnosis.. Patent WO 1998039474 A1, vom 04.03.1998
53 Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011; 11: 5
54 Rote Liste Service GmbH. Rote Liste 2013. Frankfurt/Main: Rote Liste Service GmbH; 2013
55 Banch Clausen F. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Prenat Diagn 2014; 34: 1-7
56 Statistisches Bundesamt. Geborene und Gestorbene 2012. Im Internet: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Geburten/Tabellen/GeboreneGestorbene.html Stand: 03.03.2014